Top

Published in:

17-02-2023 | Multiple Sclerosis | Review

Selective inhibition of peptidyl-arginine deiminase (PAD): can it control multiple inflammatory disorders as a promising therapeutic strategy?

Authors: Dibya Sundar Padhy, Partha Palit, Abu Md Ashif Ikbal, Nirupam Das, Dilip Kumar Roy, Sugato Banerjee

Published in: Inflammopharmacology | Issue 2/2023

Abstract

Peptidyl arginine deiminases (PADs) are a family of post-translational modification enzymes that irreversibly citrullinate (deiminate) arginine residues of protein and convert them to a non-classical amino acid citrulline in the presence of calcium ions. It has five isotypes, such as PAD1, PAD2, PAD3, PAD4, and PAD6, found in mammalian species. It has been suggested that increased PAD expression in various tissues contributes to the development of multiple inflammatory diseases, including rheumatoid arthritis (RA), cancer, diabetes, and neurological disorders. Elevation of PAD enzyme expression depends on several factors like rising intracellular Ca²⁺ levels, oxidative stress, and proinflammatory cytokines. PAD inhibitors originating from natural or synthetic sources can be used as a novel therapeutic approach concerning inflammatory disorders. Here, we review the pathological role of PAD in several inflammatory disorders, factors that trigger PAD expression, epigenetic role and finally, decipher the therapeutic approach of PAD inhibitors in multiple inflammatory disorders.

Acharya NK et al (2012) Neuronal PAD4 expression and protein citrullination: possible role in production of autoantibodies associated with neurodegenerative disease. J Autoimmun 38(4):369–380. https://doi.org/10.1016/j.jaut.2012.03.004 CrossRefPubMed

Aliko A et al (2019) Discovery of novel potential reversible peptidyl arginine deiminase inhibitor. Int J Mol Sci 20(9):2174. https://doi.org/10.3390/IJMS20092174 CrossRefPubMedPubMedCentral

Arif M, Kato T (2009) Increased expression of PAD2 after repeated intracerebroventricular infusions of soluble Aβ25–35 in the Alzheimer’s disease model rat brain: effect of memantine. Cell Mol Biol Lett. https://doi.org/10.2478/s11658-009-0029-x CrossRefPubMedPubMedCentral

Arita K et al (2004) Structural basis for Ca ²⁺-induced activation of human PAD4. Nat Struct Mol Biol 11(8):777–783. https://doi.org/10.1038/nsmb799 CrossRefPubMed

Beato M, Sharma P (2020) Peptidyl arginine deiminase 2 (PADI2)-mediated arginine citrullination modulates transcription in cancer. Int J Mol Sci 21(4):1351. https://doi.org/10.3390/ijms21041351 CrossRefPubMedPubMedCentral

Berthelot J-M et al (2017) NETosis: at the crossroads of rheumatoid arthritis, lupus, and vasculitis. Jt Bone Spine 84(3):255–262. https://doi.org/10.1016/j.jbspin.2016.05.013 CrossRef

Bicker KL, Thompson PR (2013) The protein arginine deiminases: structure, function, inhibition, and disease. Biopolymers 99(2):155–163. https://doi.org/10.1002/bip.22127 CrossRefPubMedPubMedCentral

Bruggeman Y et al (2021) Targeting citrullination in autoimmunity: insights learned from preclinical mouse models. Expert Opin Ther Targets 25(4):269–281. https://doi.org/10.1080/14728222.2021.1918104 CrossRefPubMed

Chan MM-Y et al (1997) Inhibition of inducible nitric oxide synthase gene expression and enzyme activity by epigallocatechin gallate, a natural product from green tea. Biochem Pharmacol 54(12):1281–1286. https://doi.org/10.1016/S0006-2952(97)00504-2 CrossRefPubMed

Cherian C, Jannet Vennila J, Sharan L (2019) Marine bromophenols as an effective inhibitor of virulent proteins (peptidyl arginine deiminase, gingipain R and hemagglutinin A) in Porphyromas gingivalis. Arch Oral Biol 100:119–128. https://doi.org/10.1016/j.archoralbio.2019.02.016 CrossRefPubMed

Cherrington BD et al (2012) ’Potential role for PAD2 in gene regulation in breast cancer cells. PLoS One 7(7):e41242. https://doi.org/10.1371/journal.pone.0041242 CrossRefPubMedPubMedCentral

Chumanevich AA, Causey CP, Knuckley BA, Jones JE, Poudyal D, Chumanevich AP, Davis T, Matesic LE, Thompson PR, Hofseth LJ (2011) Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor. Am J Physiol Gastrointest Liver Physiol 300(6):G929–G938. https://doi.org/10.1152/ajpgi.00435.2010 CrossRefPubMedPubMedCentral

Ciesielski O et al (2022) Citrullination in the pathology of inflammatory and autoimmune disorders: recent advances and future perspectives. Cell Mol Life Sci 79(2):94. https://doi.org/10.1007/s00018-022-04126-3 CrossRefPubMedPubMedCentral

Colasanti T et al (2022) Belimumab decreases autophagy and citrullination in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Cells. https://doi.org/10.3390/cells11020262 CrossRefPubMedPubMedCentral

Crocker M et al (2021) Umpolung amide synthesis mechanistic studies, development of a new N-aryl amide synthesis, and α-oxy-and α-thio-nitroalkanes in the BAM-catalyzed aza-Henry reaction. Doctoral Dissertation, Vanderbilt University

Curran AM et al (2020) PAD enzymes in rheumatoid arthritis: pathogenic effectors and autoimmune targets. Nat Rev Rheumatol 16(6):301–315. https://doi.org/10.1038/s41584-020-0409-1 CrossRefPubMed

Cuthbert GL et al (2004) Histone deimination antagonizes arginine methylation. Cell 118(5):545–553. https://doi.org/10.1016/j.cell.2004.08.020 CrossRefPubMed

Damgaard D et al (2016) Reduced glutathione as a physiological co-activator in the activation of peptidylarginine deiminase. Arthritis Res Ther 18(1):102. https://doi.org/10.1186/s13075-016-1000-7 CrossRefPubMedPubMedCentral

Deng L et al (2020) ’The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct Target Ther 5(1):11. https://doi.org/10.1038/s41392-020-0107-0 CrossRefPubMedPubMedCentral

Deng H, Lin C, Garcia-Gerique L, Fu S, Cruz Z, Bonner EE, Rosenwasser M, Rajagopal S, Sadhu MN, Gajendran C, Zainuddin M, Gosu R, Sivanandhan D, Shelef MA, Nam B, Vogl DT, Gabrilovich DI, Nefedova Y (2022) A novel selective inhibitor JBI-589 targets PAD4-mediated neutrophil migration to suppress tumor progression. Can Res 82(19):3561–3572. https://doi.org/10.1158/0008-5472.CAN-21-4045 CrossRef

Dreyton CJ et al (2014) Insights into the mechanism of streptonigrin-induced protein arginine deiminase inactivation. Bioorg Med Chem 22(4):1362–1369. https://doi.org/10.1016/j.bmc.2013.12.064 CrossRefPubMedPubMedCentral

Esposito G et al (2007) ’Peptidylarginine deiminase (PAD) 6 is essential for oocyte cytoskeletal sheet formation and female fertility. Mol Cell Endocrinol 273(1–2):25–31. https://doi.org/10.1016/j.mce.2007.05.005 CrossRefPubMed

Fearon WR (1939) The carbamide diacetyl reaction: a test for citrulline. Biochem J 33(6):902–907. https://doi.org/10.1042/bj0330902 CrossRefPubMedPubMedCentral

Grigoriadis A et al (2006) Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data. Breast Cancer Res 8(5):R56. https://doi.org/10.1186/bcr1604 CrossRefPubMedPubMedCentral

Guo W et al (2017) Investigating the expression, effect and tumorigenic pathway of PADI2 in tumors. Onco Targets Ther 10:1475–1485. https://doi.org/10.2147/OTT.S92389 CrossRefPubMedPubMedCentral

Ham A et al (2014) Peptidyl arginine deiminase-4 activation exacerbates kidney ischemia-reperfusion injury. Am J Physiol Renal Physiol 307(9):F1052–F1062. https://doi.org/10.1152/ajprenal.00243.2014 CrossRefPubMedPubMedCentral

Hassan Zadeh A et al (2020) Characterizing basal-like triple-negative breast cancer using gene expression analysis: a data mining approach. Expert Syst Appl 148:113253. https://doi.org/10.1016/j.eswa.2020.113253 CrossRef

Hu Y et al (2004) Synergistic interactions of lipids and myelin basic protein. Proc Natl Acad Sci 101(37):13466–13471. https://doi.org/10.1073/pnas.0405665101 CrossRefPubMedPubMedCentral

Ishigami A et al (2005) ‘Abnormal accumulation of citrullinated proteins catalyzed by peptidylarginine deiminase in hippocampal extracts from patients with Alzheimer’s disease. J Neurosci Res 80(1):120–128. https://doi.org/10.1002/jnr.20431 CrossRefPubMed

Iyengar KP, Vaish A, Nune A (2022) Anti-cyclic citrullinated peptide antibody (ACPA) and rheumatoid arthritis: clinical relevance. J Clin Orthop Trauma 24:101729. https://doi.org/10.1016/j.jcot.2021.101729 CrossRefPubMed

Jang B et al (2010) ‘Involvement of peptidylarginine deiminase-mediated post-translational citrullination in pathogenesis of sporadic Creutzfeldt-Jakob disease. Acta Neuropathol 119(2):199–210. https://doi.org/10.1007/s00401-009-0625-x CrossRefPubMed

Jang B et al (2018) Myelin basic protein citrullination, a hallmark of central nervous system demyelination, assessed by novel monoclonal antibodies in prion diseases. Mol Neurobiol 55(4):3172–3184. https://doi.org/10.1007/s12035-017-0560-0 CrossRefPubMed

Jonsson M et al (2020) ’Peptidylarginine deiminase 4 (PAD4) activity in early rheumatoid arthritis. Scand J Rheumatol 49(2):87–95. https://doi.org/10.1080/03009742.2019.1641216 CrossRefPubMed

Kholia S et al (2015) ‘A novel role for peptidylarginine deiminases in microvesicle release reveals therapeutic potential of PAD inhibition in sensitizing prostate cancer cells to chemotherapy. J Extracell Vesicles 4(1):26192. https://doi.org/10.3402/jev.v4.26192 CrossRefPubMed

Knight JS, Luo W, O’Dell AA, Yalavarthi S, Zhao W, Subramanian V, Guo C, Grenn RC, Thompson PR, Eitzman DT, Kaplan MJ (2014) Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis. Circ Res 114(6):947–956. https://doi.org/10.1161/CIRCRESAHA.114.303312 CrossRefPubMedPubMedCentral

Koushik S et al (2017) PAD4: pathophysiology, current therapeutics and future perspective in rheumatoid arthritis. Expert Opin Ther Targets 21(4):433–447. https://doi.org/10.1080/14728222.2017.1294160 CrossRefPubMed

Koziel J et al (2014) Citrullination alters immunomodulatory function of LL-37 essential for prevention of endotoxin-induced sepsis. J Immunol 192(11):5363–5372. https://doi.org/10.4049/jimmunol.1303062 CrossRefPubMed

Lange S, Rocha-Ferreira E, Thei L, Mawjee P, Bennett K, Thompson PR, Subramanian V, Nicholas AP, Peebles D, Hristova M, Raivich G (2014) Peptidylarginine deiminases: novel drug targets for prevention of neuronal damage following hypoxic ischemic insult (HI) in neonates. J Neurochem 130(4):555–562. https://doi.org/10.1111/jnc.12744 CrossRefPubMedPubMedCentral

Lewis HD et al (2015) Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. Nat Chem Biol 11(3):189–191. https://doi.org/10.1038/nchembio.1735 CrossRefPubMedPubMedCentral

Li F et al (2019) ’Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells. J Exp Clin Cancer Res 38(1):414. https://doi.org/10.1186/s13046-019-1404-8 CrossRefPubMedPubMedCentral

Liu Y, Lightfoot YL, Seto N, Carmona-Rivera C, Moore E, Goel R, O’Neil L, Mistry P, Hoffmann V, Mondal S, Premnath PN, Gribbons K, Dell’Orso S, Jiang K, Thompson PR, Sun H-W, Coonrod SA, Kaplan MJ (2018) Peptidylarginine deiminases 2 and 4 modulate innate and adaptive immune responses in TLR-7–dependent lupus. JCI Insight. https://doi.org/10.1172/jci.insight.124729 CrossRefPubMedPubMedCentral

Luo Y et al (2006a) Inhibitors and inactivators of protein arginine deiminase 4: functional and structural characterization. Biochemistry 45(39):11727–11736. https://doi.org/10.1021/bi061180d CrossRefPubMed

Luo Y, Knuckley B, Lee YH, Stallcup MR, Thompson PR (2006b) A fluoroacetamidine-based inactivator of protein arginine deiminase 4: design, synthesis, and in vitro and in vivo evaluation. J Am Chem Soc 128(4):1092–1093. https://doi.org/10.1021/ja0576233 CrossRefPubMedPubMedCentral

Mastronardi FG et al (2006) Increased citrullination of histone H3 in multiple sclerosis brain and animal models of demyelination: a role for tumor necrosis factor-induced peptidylarginine deiminase 4 translocation. J Neurosci 26(44):11387–11396. https://doi.org/10.1523/JNEUROSCI.3349-06.2006 CrossRefPubMedPubMedCentral

Moscarello MA et al (2002) Peptidylarginine deiminase: a candidate factor in demyelinating disease. J Neurochem 81(2):335–343. https://doi.org/10.1046/j.1471-4159.2002.00834.x CrossRefPubMed

Moscarello MA, Lei H, Mastronardi FG, Winer S, Tsui H, Li Z, Ackerley C, Zhang L, Raijmakers R, Wood DD (2013) Inhibition of peptidyl-arginine deiminases reverses protein- hypercitrullination and disease in mouse models of multiple sclerosis. DMM Dis Models Mech 6(2):467–478. https://doi.org/10.1242/dmm.010520 CrossRef

Naegele M, Tillack K, Reinhardt S, Schippling S, Martin R, Sospedra M (2012) Neutrophils in multiple sclerosis are characterized by a primed phenotype. J Neuroimmunol 242(1–2):60–71. https://doi.org/10.1016/j.jneuroim.2011.11.009 CrossRefPubMed

Nicholas AP (2011) Dual immunofluorescence study of citrullinated proteins in Parkinson diseased substantia nigra. Neurosci Lett 495(1):26–29. https://doi.org/10.1016/j.neulet.2011.03.028 CrossRefPubMed

Pritzker LB, Moscarello MA (1998) A novel microtubule independent effect of paclitaxel: the inhibition of peptidylarginine deiminase from bovine brain. Biochim Biophys Acta 1388(1):154–160. https://doi.org/10.1016/S0167-4838(98)00175-7 CrossRefPubMed

Qin H et al (2017) PAD1 promotes epithelial-mesenchymal transition and metastasis in triple-negative breast cancer cells by regulating MEK1-ERK1/2-MMP2 signaling. Cancer Lett 409:30–41. https://doi.org/10.1016/j.canlet.2017.08.019 CrossRefPubMedPubMedCentral

Raijmakers R et al (2006) Experimental autoimmune encephalomyelitis induction in peptidylarginine deiminase 2 knockout mice. J Comp Neurol 498(2):217–226. https://doi.org/10.1002/cne.21055 CrossRefPubMed

Reddy MVK et al (2021) In-vitro evaluation of antioxidant and anticholinesterase activities of novel pyridine, quinoxaline and s-triazine derivatives. Environ Res 199:111320. https://doi.org/10.1016/j.envres.2021.111320 CrossRefPubMed

Rodríguez-Rodríguez M et al (2017) Activation of peptidylarginine deiminase in the salivary glands of Balb/c mice drives the citrullination of ro and la ribonucleoproteins. J Immunol Res 2017:1–14. https://doi.org/10.1155/2017/8959687 CrossRef

Rohrbach AS et al (2012) Activation of PAD4 in NET formation. Front Immunol. https://doi.org/10.3389/fimmu.2012.00360 CrossRefPubMedPubMedCentral

Ruiz-Hernández S et al (2022) Virtual screening and in vitro evaluation identify methotrexate and testosterone are inhibitors of protein arginine deiminase 4. Arch Med Res 53(3):280–288. https://doi.org/10.1016/j.arcmed.2022.02.003 CrossRef

Sancandi M et al (2020) Protein deimination signatures in plasma and plasma-EVs and protein deimination in the brain vasculature in a rat model of pre-motor Parkinson’s disease. Int J Mol Sci 21(8):2743. https://doi.org/10.3390/ijms21082743 CrossRefPubMedPubMedCentral

Seaman A et al (2016) ’Anti-peptidyl-arginine deaminase 3 (PAD3) antibodies as a promising marker to measure joint damage in patients with rheumatoid arthritis. Autoimmun Rev 15(7):776–780. https://doi.org/10.1016/j.autrev.2016.03.016 CrossRefPubMed

Tjin CC et al (2018) Synthesis and biological evaluation of an indazole-based selective protein arginine deiminase 4 (PAD4) inhibitor. ACS Med Chem Lett 9(10):1013–1018. https://doi.org/10.1021/acsmedchemlett.8b00283 CrossRefPubMedPubMedCentral

Tu R, Grover HM, Kotra LP (2016) Peptidyl arginine deiminases and neurodegenerative diseases. Curr Med Chem 23:104–114 CrossRefPubMed

Wang S, Wang Y (2013) Peptidylarginine deiminases in citrullination, gene regulation, health and pathogenesis. Biochim Biophys Acta 1829(10):1126–1135. https://doi.org/10.1016/j.bbagrm.2013.07.003 CrossRefPubMedPubMedCentral

Wang Y et al (2004) Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 306(5694):279–283. https://doi.org/10.1126/science.1101400 CrossRefPubMed

Wang Y, Li M, Stadler S, Correll S, Li P, Wang D, Hayama R, Leonelli L, Han H, Grigoryev SA, Allis CD, Coonrod SA (2009) Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation. J Cell Biol 184(2):205–213. https://doi.org/10.1083/jcb.200806072 CrossRefPubMedPubMedCentral

Wang S, Chen XA, Hu J, Jiang J, Li Y, Chan-Salis KY, Gu Y, Chen G, Thomas C, Pugh BF, Wang Y (2015) ATF4 gene network mediates cellular response to the anticancer PAD inhibitor YW3-56 in triple-negative breast cancer cells. Mol Cancer Ther 14(4):877–888. https://doi.org/10.1158/1535-7163.MCT-14-1093-T CrossRefPubMedPubMedCentral

Wang L et al (2022) Peptidylarginine deiminase and Alzheimer’s disease. J Alzheimers Dis 85(2):473–484. https://doi.org/10.3233/JAD-215302 CrossRefPubMed

Wiersma VR et al (2019) Galectin-9 is a possible promoter of immunopathology in rheumatoid arthritis by activation of peptidyl arginine deiminase 4 (PAD-4) in granulocytes. Int J Mol Sci 20(16):4046. https://doi.org/10.3390/ijms20164046 CrossRefPubMedPubMedCentral

Willis VC, Banda NK, Cordova KN, Chandra PE, Robinson WH, Cooper DC, Lugo D, Mehta G, Taylor S, Tak PP, Prinjha RK, Lewis HD, Holers VM (2017) Protein arginine deiminase 4 inhibition is sufficient for the amelioration of collagen-induced arthritis. Clin Exp Immunol 188(2):263–274. https://doi.org/10.1111/cei.12932 CrossRefPubMedPubMedCentral

Zhang X et al (2012) Peptidylarginine deiminase 2-catalyzed histone H3 arginine 26 citrullination facilitates estrogen receptor α target gene activation. Proc Natl Acad Sci 109(33):13331–13336. https://doi.org/10.1073/pnas.1203280109 CrossRefPubMedPubMedCentral

Title: Selective inhibition of peptidyl-arginine deiminase (PAD): can it control multiple inflammatory disorders as a promising therapeutic strategy?
Authors: Dibya Sundar Padhy
Partha Palit
Abu Md Ashif Ikbal
Nirupam Das
Dilip Kumar Roy
Sugato Banerjee
Publication date: 17-02-2023
Publisher: Springer International Publishing
Keywords: Multiple Sclerosis
Rheumatoid Arthritis
Published in: Inflammopharmacology / Issue 2/2023
Print ISSN: 0925-4692
Electronic ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-023-01149-5

Keynote Webinar | Spotlight on Diet and Diabetes

Springer Medicine

Selective inhibition of peptidyl-arginine deiminase (PAD): can it control multiple inflammatory disorders as a promising therapeutic strategy?

Abstract

Keynote Webinar | Spotlight on Diet and Diabetes

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2023

Bioactive fraction from Plumeria obtusa L. attenuates LPS-induced acute lung injury in mice and inflammation in RAW 264.7 macrophages: LC/QToF-MS and molecular docking

Modulation of inflammatory mediators involved in the antinociceptive and anti-inflammatory effects of a new thioamide derivative: thiocyanoacetamide

Exploring various novel diagnostic and therapeutic approaches in treating diabetic retinopathy

Synovial mesenchymal stem cell-derived exosomal microRNA-320c facilitates cartilage damage repair by targeting ADAM19-dependent Wnt signalling in osteoarthritis rats

Adalimumab combined with erythropoietin improves recovery from spinal cord injury by suppressing microglial M1 polarization-mediated neural inflammation and apoptosis

Anti-inflammatory and antioxidant activities of Gymnema Sylvestre extract rescue acute respiratory distress syndrome in rats via modulating the NF-κB/MAPK pathway